

Active substances set

Search phrase: atezolizumab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Liver cancer

Atezolizumab

Atezolizumab, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

 **NO REIMBURSEMENT**
 **ESMO**

Tracheal, bronchus, and lung cancer

Atezolizumab

Atezolizumab as monotherapy is indicated for the first-line treatment of adult patients with metastatic nonsmall cell lung cancer (NSCLC) whose tumours have a PD-L1 expression $\geq 50\%$ tumour cells (TC) or $\geq 10\%$ tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC. Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Atezolizumab.

 **REIMBURSEMENT WITH RESTRICTIONS**
 **ESMO**

Malignant breast cancer

Atezolizumab

Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with

 **NO REIMBURSEMENT**
 **ESMO**

unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression \geq 1% and who have not received prior chemotherapy for metastatic disease.

Malignant bladder cancer

Atezolizumab

Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):

- after prior platinum-containing chemotherapy, or
- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression \geq 5% .

 **NO REIMBURSEMENT**

 **ESMO**